Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2024-04-28 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
2023年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度董事会审计委员会履职情况报告" which translates to "2023 Annual Report on the Board Audit Committee's Performance." It details the audit committee's activities, meetings, supervision of external and internal audits, evaluation of internal controls, and overall assessment for the year 2023. The document is a report on the audit committee's work rather than a full annual report or standalone audit report. It is not an announcement or a brief notice but a substantive report on audit committee duties and oversight. This fits best under the category of Audit Report / Information (AR), which includes reports on audit results and applied accounting principles but excludes full annual reports. The document length is 1794 characters, which is sufficient for a detailed committee report but not a full annual report. Therefore, the classification is AR with high confidence. FY 2023
2024-04-28 Chinese
第五届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the third meeting of the fifth board of directors of Guangdong Yongshun Biopharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to various reports and announcements that are disclosed elsewhere on the Beijing Stock Exchange information platform. The document does not contain the full reports themselves but rather summarizes the board's decisions and approvals, including references to the annual report, financial reports, audit reports, and other filings that are published separately. This type of document is a formal announcement of board meeting resolutions, which fits the category of Board/Management Information (MANG). It is not the full annual report, audit report, or financial report, nor is it a call transcript or investor presentation. The document length is sufficient and detailed, but it is clearly a board meeting resolution announcement.
2024-04-28 Chinese
第五届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of various reports and proposals including the 2023 Supervisory Board Work Report, 2023 Annual Report, 2023 Financial Final Report, 2024 Financial Budget Report, 2023 Equity Distribution Plan, and other related matters. The document references that the full reports are disclosed separately on the Beijing Stock Exchange information platform with specific announcement numbers. The document itself does not contain the full financial reports or detailed financial data but rather the resolutions passed in the Supervisory Board meeting. It is a formal announcement of meeting resolutions and approvals, not the reports themselves. Therefore, it fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution disclosure, rather than an Annual Report (10-K) or Interim Report (IR). The document length is 3433 characters, which is relatively short and consistent with an announcement rather than a full report.
2024-04-28 Chinese
2023 年度独立董事述职报告（袁英红）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2023" from Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the independent director's attendance at board meetings, opinions on various board resolutions, communication with audit institutions, and efforts to protect investor rights during the year 2023. The content is a detailed report of the independent director's duties and activities over the year, not an announcement or a brief summary. It does not contain financial statements or earnings data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a proxy solicitation or voting results announcement. It is a management-related report focusing on board activities and governance oversight by an independent director. Therefore, the best fitting category is Board/Management Information (MANG). The document length is 3076 characters, which is sufficient for a detailed report but not a full annual report. Hence, the classification is MANG with high confidence.
2024-04-28 Chinese
董事会关于独立董事独立性自查情况的专项报告
Governance Information Classification · 95% confidence The document is a special report from the board regarding the independence of independent directors, referencing regulatory requirements from the China Securities Regulatory Commission and Beijing Stock Exchange guidelines. It is a focused governance-related disclosure about board members' independence, not a full annual report, audit report, or financial statement. The content aligns with governance information about board structure and compliance with independence rules. The document length is short and specific to board governance matters, fitting the Governance Information (CGR) category.
2024-04-28 Chinese
会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of the accounting firm Tianjian CPA Firm for the audit work conducted for the fiscal year 2023. It details the firm's qualifications, resources, audit plan, quality management, and overall assessment of their audit work. The document does not contain the actual audit report or financial statements but rather an assessment of the auditor's performance and compliance with auditing standards. It is not an Annual Report (10-K) or the Audit Report itself but an audit-related information disclosure. Given the content focuses on audit work evaluation and auditor qualifications, the most appropriate classification is Audit Report / Information (AR). The document length is 2598 characters, which is consistent with a detailed audit information disclosure rather than a brief announcement or certification. Therefore, the classification is AR with high confidence. FY 2023
2024-04-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.